anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Progressive apraxia of speech (PAOS) is a neurodegenerative motor-speech disorder that most commonly arises from a four-repeat tauopathy. Recent studies have established that progressive apraxia of speech is not a homogenous disease but rather there are distinct subtypes: the phonetic subtype is characterized by distorted sound substitutions, the prosodic subtype by slow and segmented speech and the mixed subtype by a combination of both but lack of predominance of either. There is some evidence that cross-sectional patterns of neurodegeneration differ across subtypes, although it is unknown whether longitudinal patterns of neurodegeneration differ. We examined longitudinal patterns of atrophy on MRI, hypometabolism on 18F-fluorodeoxyglucose-PET and tau uptake on flortaucipir-PET in a large cohort of subjects with PAOS that had been followed for many years. Ninety-one subjects with PAOS (51 phonetic, 40 prosodic) were recruited by the Neurodegenerative Research Group. Of these, 54 (27 phonetic, 27 prosodic) returned for annual follow-up, with up to seven longitudinal visits (total visits analysed = 217). Volumes, metabolism and flortaucipir uptake were measured for subcortical and cortical regions, for all scans. Bayesian hierarchical models were used to model longitudinal change across imaging modalities with PAOS subtypes being compared at baseline, 4 years from baseline, and in terms of rates of change. The phonetic group showed smaller volumes and worse metabolism in Broca's area and the striatum at baseline and after 4 years, and faster rates of change in these regions, compared with the prosodic group. There was also evidence of faster spread of hypometabolism and flortaucipir uptake into the temporal and parietal lobes in the phonetic group. In contrast, the prosodic group showed smaller cerebellar dentate, midbrain, substantia nigra and thalamus volumes at baseline and after 4 years, as well as faster rates of atrophy, than the phonetic group. Greater hypometabolism and flortaucipir uptake were also observed in the cerebellar dentate and substantia nigra in the prosodic group. Mixed findings were observed in the supplementary motor area and precentral cortex, with no clear differences observed across phonetic and prosodic groups. These findings support different patterns of disease spread in PAOS subtypes, with corticostriatal patterns in the phonetic subtype and brainstem and thalamic patterns in the prosodic subtype, providing insight into the pathophysiology and heterogeneity of PAOS.
A method of forming a skincare composition comprising a sapropel extract, the method comprising the steps of: providing raw sapropel; placing the raw sapropel in an alkali solution; filtering the resultant solution to provide a solid and a filtrate of sapropel extract; and placing the filtrate of sapropel extract in a skincare composition. Preferably, the method further comprises the step of concentrating the filtrate of sapropel extract by removing 70-90% of water from the filtrate prior to placing it into the skincare composition. Preferably, the step of placing the raw sapropel in an alkali solution comprises placing the raw sapropel in a solution having a pH from greater than 9 to less than 11. The alkali solution may comprise a solution of water and potassium hydroxide; and/or ammonium hydroxide, sodium bicarbonate and/or sodium hydroxide. The skincare composition may be a moisturising cream, an emollient, a body butter, a balm, a shampoo, a hair conditioner, a pre-shampoo treatment, a hair lotion, a hair tonic, a shower gel or a liquid soap. Preferably, the skincare composition is useful in therapy in the treatment of one or more of eczema, dermatitis, acne, psoriasis, athletes foot and/or allergies.
Patients undergo hepatic resection. Beginning 31-56 days after surgery, patients receive mFOLFOX6 or FOLFIRI chemotherapy IV on day 1 over 3 hours. Patients receive an additional dose of fluorouracil over 46 hours using a portable pump. Treatment repeats every 2 weeks for 12 cycles.
INTRODUCTION: Screening for atrial fibrillation (AF) in the general population may help identify individuals at risk, enabling further assessment of risk factors and institution of appropriate treatment. Algorithms deployed on wearable technologies such as smartwatches and fitness bands may be trained to screen for such arrhythmias. However, their performance needs to be assessed for safety and accuracy prior to wide-scale implementation.
METHODS AND ANALYSIS: This study will assess the ability of the WHOOP strap to detect AF using its WHOOP Arrhythmia Notification Feature (WARN) algorithm in an enriched cohort with a 2:1 distribution of previously diagnosed AF (persistent and paroxysmal) and healthy controls. Recruited participants will collect data for 7 days with the WHOOP wrist-strap and BioTel ePatch (electrocardiography gold-standard). Primary outcome will be participant level sensitivity and specificity of the WARN algorithm in detecting AF in analysable windows compared with the ECG gold-standard. Similar analyses will be performed on an available epoch-level basis as well as comparison of these findings in important subgroups.
ETHICS AND DISSEMINATION: The study was approved by the ethics board at the study site. Participants will be enrolled after signing an online informed consent document. Updates will be shared via clinicaltrials.gov. The data obtained from the conclusion of this study will be presented in national and international conferences with publication in clinical research journals.
TRIAL REGISTRATION NUMBER: NCT05809362.
Patients with ureteral stones less than 10 mm, would receive observation for stone passage, not requiring immediate surgery. There are many studies evaluating the effect of Medical expulsive therapy in treating ureteral stones, including a-blockers, and calcium channel blockers. Most of shuties concluded that the benefit of a-blockers might be among those with larger (distal) stones. There is no good method for the removal of upper ureteral calculi, except drinking water and exercising.

Recently, a new extracorporeal physical vibrational lithecbole (EPVL) device named Friend-I EPVL (Zhengzhou Fu Jian Da Medical Instrument Co., Zhengzhou, China) has proven to be an effective treatment for upper urinary tract residual calculi. The device was approved by the Chinese food and drug administration in 2012. A Simple harmonic motion technology in multi-direction was applied. The Lateral acceleration was provided by the physical vibration device in the base through the harmonic vibration wave in the horizontal direction, which induces the urinary stone separate with the kidney or ureter, and expands a moving space for the stone. Meanwhile, an axial effect was produced to push the stone by the physical vibration device in the handle through the harmonic vibration wave in the multi- direction. So, we think that EPVL may be effective in treating ureteral stones.
Hypnosis in conization is more and more use to substitute General Anesthesia (GA) in Anesthesia's field. There are few studies about this new anesthesia tool. The latter showed that it's possible to substitute GA by hypnosis. This tool could have many positive such as reduced pains, anxiety or post operative vomiting nausea (POVN). Hypnosis in conization also allows time reduction in post operative security monitoring room (SSPI), speedier hospital discharge and greater patient satisfaction. Most studies involves 1 or 2 practitioners and few patients. There is no reliable research which compare Hypnosis in conization costs and GA costs. Since 2010, anesthesia's team of Grenoble Mutualist Hospital group (GHM) realized many Hypnosis in conization surgical procedures. Half of the team had been trained to Hypnosis in conization and use it for several types of surgeries for a lot of surgeons. It's the case for conisations. Currently, the 7 gynaecologists surgeons of the team achieved between 150 and 200 per year , some of this used GA, others used Hypnosis in conization, and unusually they used " rachianesthesia ". Thus, it gives us the opportunity for studying Hypnosis in conization, without practitioner effect, for a relatively cohesive group of patients (vast majority of patients are between 30 and 50 years and they haven't any particular medical history).
Aging is a prominent risk factor for numerous chronic diseases. Understanding the shared mechanisms of aging can aid in pinpointing therapeutic targets for age-related disorders. Chronic inflammation has emerged as a pivotal mediator of aging and a determinant in various age-related chronic conditions. Recent findings indicate that C-C motif chemokine ligand 2 and receptor 2 (CCL2-CCR2) signaling, an important physiological modulator in innate immune response and inflammatory defense, plays a crucial role in aging-related disorders and is increasingly recognized as a promising therapeutic target, highlighting its significance. This review summarizes recent advances in the investigation of CCL2-CCR2 signaling in cardiovascular and neural aging, as well as in various aging-related disorders. It also explores the underlying mechanisms and therapeutic potentials in these contexts. These insights aim to deepen our understanding of aging pathophysiology and the development of aging-related diseases.
The haskap supplement will consist of a haskap berry smoothie. A twice daily dose (10-12) hours apart will be consumed for 8 weeks.
This is a post-market, multi-center, patient outcomes centered study to evaluate the on-label use of AccuFill during the Subchondroplasty procedure (SCP). Enrolled subjects will sign an informed consent form, satisfy the inclusion/exclusion criteria and have at least one bone marrow lesion, such as a cyst or stress fracture confirmed by diagnostic imaging in the foot and/or ankle joint. Demographics, medical history and medications will recorded at the time of enrollment. Surgical details including the SCP procedure, concomitant surgical procedures and intraoperative safety events will be recorded. Subjects will complete validated patient reported outcomes measures pre-operatively including the Foot Function Index (FFI) revised short form, the EQ-5D™ and numeric pain score. These measures plus a subject satisfaction survey will also be administered post-operatively at 6 weeks, 3 months, 6 months, 1 year, and 2 years. Screening for adverse events and revision surgeries will occur throughout the study.

Target enrollment is 140 patients at up to 25 clinical sites. Subjects will complete the study at 2 years or will be withdrawn if the patient undergoes revision surgery of the Subchondroplasty site.
A 350 mm2 Baerveldt glaucoma implant was placed. Follow-up visits were scheduled 1 day, 1 week, 1 month, 3 months, 6 months, 1 year postoperatively. The primary outcome measure was failure that defined as IOP \>16 mmHg or less than a 20% reduction below baseline on 2 consecutive study visits.The IOP, the use of glaucoma medications, visual acuity (VA), visual fields, bleb morphology and rates of surgical complications were secondary outcome measures.
Cardiac Electrophysiology

Separate thorough QT trials have been conducted for darunavir co-administered with ritonavir and for cobicistat. The effect of darunavir co-administered with cobicistat on the QT interval has not been evaluated.

Darunavir: In a thorough QT/QTc study in 40 healthy subjects, darunavir doses (co-administered with 100 mg ritonavir) of approximately 2 times the recommended darunavir dose did not affect the QT/QTc interval. 

Cobicistat: The effect of a single dose of cobicistat 250 mg and 400 mg (approximately 1.7 and 2.7 times the recommended dose) on QTc interval was evaluated in a randomized, placebo- and active-controlled (moxifloxacin 400 mg) four-period crossover thorough QT trial in 48 healthy subjects. In this trial, no significant QTc prolongation effect of cobicistat was detected. The dose of 400 mg cobicistat is expected to provide information on a high exposure clinical scenario. Prolongation of the PR interval was noted in subjects receiving cobicistat in the same trial. The maximum mean (95% upper confidence bound) difference in PR from placebo after baseline-correction was 9.5 (12.1) msec for 250 mg and 20.2 (22.8) msec for 400 mg of cobicistat .

Effects on Serum Creatinine

Cobicistat: The effect of cobicistat on serum creatinine was investigated in a trial in subjects with normal renal function (eGFR ≥80 mL/min, N=12) and mild-to-moderate renal impairment (eGFR 50–79 mL/min, N=18). A statistically significant decrease in the estimated glomerular filtration rate, calculated by Cockcroft-Gault method (eGFR CG) from baseline, was observed after 7 days of treatment with cobicistat 150 mg among subjects with normal renal function (-9.9 ± 13.1 mL/min) and mild-to-moderate renal impairment (-11.9 ± 7.0 mL/min). No statistically significant changes in eGFR CGwere observed compared to baseline for subjects with normal renal function or mild-to-moderate renal impairment 7 days after cobicistat was discontinued. The actual glomerular filtration rate, as determined by the clearance of probe drug iohexol, was not altered from baseline following treatment of cobicistat among subjects with normal renal function and mild-to-moderate renal impairment, indicating that cobicistat inhibits tubular secretion of creatinine, reflected as a reduction in eGFR CG, without affecting the actual glomerular filtration rate.
Similarly to how burnout syndrome is not scientifically recognized as a disease but rather as a life-management difficulty according to ICD 10, scalp burnout or skin burnout is not understood to mean a self-contained entity but rather a life-management difficulty issue. The product contains an extract of virgin witch hazel (Hamamelis virginiana) of wild populations on the basis of a mild shampoo surfactant or as a hair tonic or cream, gel, or wash cream. All preparation compositions are free of cocamidopropyl betaine and parabens. The preparation contains at least one or more of the following substances as additives: tocopherol, rosemary, urea, polidocanol, Zea mays (corn) kernel extract, glycerol and isopropyl myristate, polysorbate 80, and sulfur (biosulfur). When designed as a hair tonic, the preparation contains rosemary for metabolism and circulation and field horsetail for strengthening the connective tissue and for circulation as well as birch and nettle for stimulating healthy hair growth. When designed and used as a cream, the preparation normalizes and revitalizes tired, reddened skin prone to loosening and overdrying. The cream contains a combination of ingredients which promote the regeneration of the skin by virtue of the cell-building properties of the ingredients and the increase of the water-binding capability of the skin cells. Additionally the skin is protected from harmful influences, and the cream exhibits a remarkably good compatibility of the witch hazel preparation, in particular when used on diseased skin (eczema, smaller injuries, dry skin). Itching, reddening, sunburns, and burns can be quickly and successfully treated using the cream.
Infants were offered oral feedings beginning at 34 weeks PMA. They were offered 2 oral feedings per day for 3 days (Days 1-3). The number of oral feedings offered per day increased by 1 feeding every other day until day 14 when they were offered 8 oral feedings each day (Days 4-5, 3 oral feeds offered; Days 6-7, 4 oral feeds offered; Days 8-9, 5 oral feeds offered; Days 10-11, 6 oral feeds offered; Days 12-13, 7 oral feeds offered; Day14, 8 oral feeds offered). Any feedings not offered orally were provided by gavage.
INTRODUCTION: In the USA, patients who undergo genetic testing for hereditary cancer risk are responsible for informing relatives about their genetic test results, but many relatives never find out they might be at risk. A health system-mediated relative notification program might help fill this gap, but questions remain about the acceptability of this approach.
METHODS: We analyzed qualitative data from a single-arm, nonrandomized, mixed-methods study to understand how patients and families experienced a new health system-mediated relative notification program. We invited all study participants to participate in semi-structured telephone interviews at 6-8 weeks after return of genetic test results. We used a template analysis approach to thematically analyze interview transcripts.
RESULTS: We interviewed 32 participants, including 17 probands and 15 relatives. Relatives reported positive experiences with the notification program, noting they felt in control of decisions and appreciated genetic counselor involvement in communicating the proband's test results. Benefits of direct contact included reduced burden for probands, increased family discussions about health, and notification of relatives who otherwise would not have learned results. No participants reported adverse effects from the program.
CONCLUSION: Overall, the relative notification program was acceptable to participants and supported probands in reaching at-risk relatives who otherwise might not have been notified. These findings could inform the implementation of future genetic risk family notification programs with the potential to improve uptake of cascade testing and advance cancer prevention and early detection efforts.
NP swabs from the Adult population \>17 years, collected prospectively from adults presenting with symptoms of respiratory illness. Tested within 72 hours of collection.
FIELD: medicine, pharmacy. SUBSTANCE: the improved pharmaceutical preparation has ibuprofen and codeine (or pharmaceutically acceptable salts of any of their), a carrier containing disintegrating agent, diluting agent and lubricating agent free of stearic acid and stearate ions and taken among hydrogenated vegetable oils. The preferable preparations are directly pressed tablets that are useful in pain and inflammation treatment. Invention provides good color stability of tablets that do not change color for the time or due to the temperature effect. Tablets are stable at the storage. EFFECT: improved properties and quality of the preparation. 22 cl, 7 ex
Mini-endoscopic combined intrarenal surgery (ECIRS) offers improved advantages in the treatment of renal stones. However, the factors influencing the operative time remain poorly understood. This study aimed to identify the factors that enhance treatment planning and minimize complications. Clinical data from consecutive patients who underwent mini-ECIRS for renal stones and achieved a stone-free status between 2015 and 2021 at three high-volume centers in Japan were analyzed. The final treatment outcome was evaluated by computed tomography imaging at postoperative 1 month, and a successful outcome was defined as complete stone-free or residual stone fragments < 4 mm. Logistic and linear regression models were used to predict the operative duration of mini-ECIRS. An operative time of ≥ 120 min was significantly associated with punctured pole and body mass index (BMI), and septic shock was only observed in patients with operative times of ≥ 120 min. The multivariate model for the operative time for mini-ECIRS identified five clinical factors: punctured pole, number of stones, number of involved calyces, BMI, and preoperative nephrostomy. We believe these findings will help surgeons and patients plan suitable treatment strategies, predict the additional need for a second mini-ECIRS or retrograde intrarenal surgery alone, and avoid severe complications.
PROBLEM TO BE SOLVED: To provide a regulator for production of an osteoclast formation inhibitor, and a method for screening a substance capable of regulating the production of the osteoclast formation inhibitor. SOLUTION: This regulator for the production of the osteoclast formation inhibitor comprises a glucide as an active ingredient. The method for screening is carried out as follows. A cultured established cell line having an ability to produce the osteoclast formation inhibitor is cultured in a nutrient culture medium and a test specimen is added thereto. The cultured established cell line is then cultured in the presence of the test specimen and the amount of the osteoclast formation inhibitor released into the culture supernatant is measured. The resultant measured value is compared with a control measured value to thereby judge the test specimen to be a substance capable of regulating the production of the osteoclast formation inhibitor when the measured value of the test specimen exceeds or is below the control measured value.
Patients receive a placebo 125 mg orally once daily on day 1 and 80 mg orally once daily on days 2 and 3. Beginning 1 hour after receiving the placebo, patients will receive an infusion of cyclophosphamide infusion on day 1. During course 2, patients crossover and receive treatment as in arm I.
Chronic Obstructive Pulmonary Disease (COPD) is a term used to describe a number of lung conditions characterised by irreversible damage to the airways causing airflow obstruction. Pulmonary Rehabilitation (PR) is a broad programme that helps improve the health and well-being of people with breathing difficulties, most commonly COPD. Participation in PR leads to improvements in exercise tolerance and functional ability, as well as a reducing breathlessness in everyday activities. It is traditionally an outpatient programme based in a hospital or community setting run by a multidisciplinary team, and usually lead by physiotherapy and nursing staff. Typically it includes a physical exercise programme, and advice and education on managing a chronic lung condition. The purpose of this pilot study is to compare a six week web-based pulmonary rehabilitation programme with traditional hospital-based pulmonary rehabilitation classes for people affected by COPD.
A method for reporting a user's emergency condition by sending an emergency help request message in a TCP/IP format to an emergency service center (ESC). The help request message may be sent over the Internet to advantageously harness the data transmission resources provided by the Internet. A support service provider may commercially provide such an emergency reporting service to a group of subscribers. The service provider may receive emergency requests from the subscribers and may send those requests over the Internet to the emergency service center. The service provider may also convert any non-TCP/IP message received from the subscriber into a TCP/IP message prior to sending the message to the ESC. A per-usage fee or a flat subscription fee may be charged by the service provider to allow users to report emergency conditions over the Internet. The support service provider thus coordinates the emergency help on behalf of the user. Internet-based emergency message delivery may be useful in many situations, for example, when the person in need of help is mute, disabled or in a situation that prevents the person from orally requesting emergency help from the ESC.